Alkagesta took part in the Commodities Innovation Awards 2026 in Geneva as a Bronze sponsor, according to a report published by the company. It said representatives from its board and executive team attended the event, which recognised innovation and achievement within the commodities industry. The report did not name the representatives who attended.

The awards were jointly created by Ampersand World and Swiss business magazine Bilan. They focus on the Swiss commodities sector and its efforts to develop solutions to challenges facing the global economy. Alkagesta described the gathering as an opportunity to bring together industry participants around innovation, collaboration and the relationships it considers important to the sector’s development.

The 2026 programme covered seven categories: technological innovation, finance innovation, market and trading innovation, sustainability innovation, shipping innovation, supply chain and logistics innovation, and a special jury award. A Personality of the Year award was also included. Alkagesta’s account focused on its sponsorship and participation rather than detailing the recipients of the awards or the projects recognised.

Geneva houses Alkagesta’s biofuels and chartering desks and is central to its European operations, the company said. It presented its support for the awards as reflecting a belief that closer industry cooperation and innovation are needed to respond to geopolitical disruption, pressures associated with the energy transition and increasingly complex supply chains. These were the company’s stated reasons for backing the event.

Alkagesta also said it had been entering additional commodity areas during 2026, expanding sustainable fuels infrastructure and strengthening its presence in European and Asian markets. It did not provide investment figures or identify specific projects in the report. The company linked its engagement with the Swiss commodities community to partnerships that it sees as supporting its longer-term growth.

Read the original announcement on Alkagesta.